Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.4085
+0.0456 (12.57%)
At close: Jul 8, 2026, 4:00 PM EDT
0.4010
-0.0075 (-1.84%)
After-hours: Jul 8, 2026, 6:52 PM EDT
Nexalin Technology Employees
Nexalin Technology had 8 employees as of December 31, 2025. The number of employees increased by 2 or 33.33% compared to the previous year.
Employees
8
Change (1Y)
2
Growth (1Y)
33.33%
Revenue / Employee
$34,448
Profits / Employee
-$1,041,335
Market Cap
8.80M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 2 | 33.33% | 8 | 0 |
| Dec 31, 2024 | 6 | 0 | - | 6 | 0 |
| Dec 31, 2023 | 6 | 0 | - | 6 | 0 |
| Dec 31, 2022 | 6 | -4 | -40.00% | 6 | 0 |
| Jun 30, 2022 | 3 | 1 | 50.00% | 3 | 0 |
| Mar 31, 2022 | 10 | 6 | 150.00% | 2 | 8 |
| Dec 31, 2021 | 10 | 6 | 150.00% | 2 | 8 |
| Sep 30, 2021 | 2 | -2 | -50.00% | 2 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Trinity Biotech | 287 |
| Vivos Therapeutics | 270 |
| Co-Diagnostics | 115 |
| VolitionRx | 67 |
| Intelligent Bio Solutions | 55 |
| Beyond Air | 54 |
| Biomerica | 54 |
| enVVeno Medical | 33 |
NXL News
- 9 days ago - Nexalin Technology Proxy statement: Proxy filing - Filings
- 15 days ago - Nexalin Technology investigator wins award for neurostimulation research - TheFly
- 15 days ago - Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform - GlobeNewsWire
- 22 days ago - Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - GlobeNewsWire
- 4 weeks ago - Nexalin Technology completes neurostimulation protocol trial - TheFly
- 4 weeks ago - Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan. - GlobeNewsWire
- 4 weeks ago - Nexalin Technology Registration statement - Filings
- 4 weeks ago - Nexalin Technology Quarterly report - Filings